news
Novel methodology increases resolution in oligodendrocyte proteomics
Brazilian researchers combine mass spectrometry, 2-D liquid chromatography and ion mobility to identify over 10,000 proteins in brain cells possibly involved in schizophrenia.
List view / Grid view
Proteomics
article
The future of bioanalysis with microchip chromatography
Much rests on the further development of bioanalytical technologies which allow the highest level of sensitivity on small samples, and robust, high reproducibility across large populations. Johan Devenyns, CEO PharmaFluidics, explains further...
news
Researchers discover new targets for approved cancer drug ceritinib
New study shows ALK inhibitor ceritinib may have the ability to be used for more than ALK-rearranged non-small cell lung cancer...
news
Computer model shows an optimal anti-amyloid treatment
A group of scientists have created a computer model to analyse amyloid beta accumulation using published papers and clinical studies...
article
Your next clinical biomarker will be assayed by mass spectrometry….or not!
23 December 2014 | By Axel Ducret, Biochemist
This article will focus on some of the critical aspects of transition biomarkers discovered in classical (MS-based) proteomics workflows and on the challenges to be met before validated assays can become more routine in the clinical laboratory...
article
Engineering cells and proteins – creating pharmaceuticals
5 September 2014 | By Marco Casteleijn & Dominique Richardson, University of Helsinki
Pharmaceutical biotechnology is big business; it currently consists of 1/6 of the total volume of the pharmaceutical market and continues to grow steadily. Expression of therapeutic proteins is mainly done in living cells, although ‘cell free protein synthesis’ (CFPS) or ‘in-vitro transcription translation’ (IVTT) is beginning to emerge as an…
article
Issue #6 2013 – Digital edition
In Issue #6 2013: PAT in-depth focus, Lab Automation, Proteomics, Next Gen Sequencing, Screening in-depth focus, Microbiology...
article
Pharmaceutical proteomics: a journey from discovery and characterisation of targets to development of high-throughput assays
15 December 2013 | By Joerg Reinders, Institute of Functional Genomics, University of Regensburg
Proteomics has evolved during the last few years from a time-intensive, cost-intensive and hard-to-reproduce technique in basic research to a versatile and reliable tool in various areas of pharmaceutical research. The exploding progress in mass-spectrometry-compatible protein and peptide-separation methods led to the development of new approaches particularly suited for monitoring…
article
Label-free quantitative proteomics: Why has it taken so long to become a mainstream approach?
13 June 2013 | By Thierry Le Bihan, SynthSys and Institute of Structural and Molecular Biology, University of Edinburgh
In recent years, mass spectrometry (MS) based proteomics has moved from being a qualitative tool (used to mainly identify proteins) to a more reliable analysis tool, allowing relative quantitation as well as absolute quantitation of a large number of proteins. However, the developed quantitative methods are either specific for certain…
article
The role of proteomics in the development of personalised cancer medicine
18 April 2013 | By Pedro R. Cutillas, MRC Clinical Sciences Centre, Imperial College London
Not all cancer patients, even those with the same tumour type, respond to therapy equally well. An understanding of this heterogeneity at the molecular level is crucial for further advances in the development of cancer therapies. Discerning the mechanisms of cancer heterogeneity will lead to a better selection of the…
article
The need for proteomic-based biomarkers in the drug development pipeline
10 July 2012 | By Paul C. Guest, Department of Chemical Engineering and Biotechnology, University of Cambridge and Sabine Bahn Department of Chemical Engineering and Biotechnology, University of Cambridge & Department of Neuroscience, Erasmus Medical Centre
Pharmaceutical companies are under increasing pressure to improve their efficiency and returns on drug discovery projects. This is a daunting task considering that the average drug costs approximately one billion US dollars to develop and takes around 12 years from initial discovery to reach the market1. In addition, approximately 70…
article
Mass Spectrometry In-Depth Focus 2012
In this free to view Mass Spectrometry In-Depth Focus: Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics; Quantification of membrane drug transporters and application in drug discovery and development; Mass spectrometry leaders roundtable...
article
The Forgotten Fragments
19 October 2011 | By Ross Chawner and Claire E. Eyers, Michael Barber Centre for Mass Spectrometry, University of Manchester
Identification of protein biomarkers and the evaluation of changes in protein expression following drug treatment rely on both the generation of peptides from cellular proteins, and the acquisition and interpretation of spectra generated by tandem mass spectrometry (MS/MS). Acquisition of MS/MS spectra in a datadependent manner means that a significant…
news
Thermo Fisher Scientific scientist Dr. Alexander Makarov receives inaugural HUPO Science and Technology Award
Thermo Fisher Scientific Inc., the world leader in serving science, has announced that Dr. Alexander Makarov, its director of global research for life sciences mass spectrometry, has received the first HUPO Science and Technology Award from the Human Proteome Organization (HUPO).
news
Thermo Fisher Scientific introduces expanded chromatography portfolio
Thermo Fisher Scientific Inc., the world leader in serving science, today announced it will show its expanded portfolio of market-leading chromatography solutions within the Thermo Scientific and Dionex booths at HPLC 2011, a first since Thermo Fisher acquired Dionex.
